Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.
The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.
July 2025 in “Journal of Investigative Dermatology”
March 2024 in “Journal of the American Academy of Dermatology” Taking medication for hair loss might cause sexual problems.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
33 citations
,
June 2009 in “Journal of Cutaneous Pathology” Erlotinib can cause nonscarring hair loss and itchy skin.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
July 2026 in “Advances in Therapy” Clinicians prefer JAK inhibitors that regrow scalp hair quickly and effectively for alopecia areata.
January 2026 in “Open MIND” Targeting the PIEZO1 and MLCK axis may offer a new treatment for hair loss.
December 2023 in “Journal of health and rehabilitation research” Oral Apremilast effectively treats alopecia areata in most patients.
January 2025 in “International Journal for Research in Applied Science and Engineering Technology” Eclipta alba promotes hair growth and supports liver health.
7 citations
,
July 2018 in “Biological & Pharmaceutical Bulletin” Phyllanthus urinaria extract may help treat hair loss by blocking a hair-related enzyme.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
July 2026 in “American Journal of Clinical Dermatology” Oral JAK inhibitors help regrow hair in alopecia areata with manageable side effects.
July 2025 in “International Journal of Health and Medicine” Tamsulosin and solifenacin together effectively reduce symptoms in BPH patients.
4 citations
,
November 2017 in “The Journal of Dermatology” Sorafenib may cause hair loss in a way similar to alopecia areata.
September 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” AR-27 E-Chol siRNA can effectively promote hair regrowth for androgenetic alopecia.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
6 citations
,
March 2015 in “Journal of Endocrinological Investigation” Taking both finasteride and dutasteride for prostate issues may raise the risk of heart problems.
1 citations
,
January 2017 in “Pharmaceutica Analytica Acta” The research confirmed that certain methods are reliable for standardizing Eclipta alba and ensuring its safety and quality in herbal products.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
63 citations
,
December 2013 in “PLoS ONE” Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.
1 citations
,
August 2022 in “JAAD case reports” Tofacitinib and oral minoxidil may help treat Sisaipho alopecia areata.
June 2015 in “Reactions Weekly” A man developed alopecia areata after starting cancer treatment with vandetanib.
5 citations
,
January 2021 in “Dermatology Online Journal” An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.